tailieunhanh - TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model

Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms. | TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN